Delay is ONE quarter only. Previous expectation was to start the commercialization of NexGen in Q1 2014. Now it may start in Q2 2014.
Quarterly revenue estimates were 9,51 Mio. Postet revenue for 2nd quarter was 11,1 Mio. That's an upside of round about 17%.
Earning estimates were -0,17 per share. Earnings for 2nd quarter were -0,13 per share. That's an upside of round about 25%.
42 additional analyzers were placed in first quarter 2013. In Q4 2012 they placed 42 additional analyzers too. In Year 2012 they placed 130 additional analyzers. GNMK expectation was 150 additional analyzers in year 2013. Investment into own direct sales force is ongoing. They expect to be at 30 people by the end of 2013 and then 40 by the end of 2014. So the revenue and additional analyzer expectations should be keeped I think.